Contents

Search


geographic atrophy

Etiology: - macular degeneration - advanced dry form of age-related macular degeneration Epidemiology: - affects > 1 million people in the U.S. & 5 million people worldwide Complications: - major cause of adult blindness Management: - pegcetacoplan (Syfovre) injection administered every 25-60 days (FDA-approved) - maximum benefit between 18-24 months after initiating treatment. - avacincaptad pegol (Izeray) - photovoltaic retina implant microarray (PRIMA) system - combines a subretinal photovoltaic implant & glasses that project near-infrared light to the implant in order to restore sight to areas of central retinal atrophy [2]

General

retinal disease

References

  1. Marcus A FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. Medscape. February 17, 2023 https://www.medscape.com/viewarticle/988460
  2. Holz FG, Le Mer Y, Muqit MMK et al Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. NEJM 2025 October 20 Not yet indexed in PubMed https://www.nejm.org/doi/full/10.1056/NEJMoa2501396 - Drew L People with blindness can read again after retinal implant. Nature News. 2025. Oct 20. https://www.nature.com/articles/d41586-025-03420-x